表皮生长因子受体（EGFR）抑制剂耐药中的一个问题：支原体和胞苷脱氨酶在降低肺癌患者奥希替尼活性方面是否起作用？ - Suppr

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

作者信息

Leonetti Alessandro, Carbone Daniela, Gregori Alessandro, Tiseo Marcello, Peters Godefridus J, Deng Dongmei, Giovannetti Elisa

机构信息

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Medical Oncology Unit, University Hospital of Parma, Parma, Italy.

出版信息

J Cancer Res Clin Oncol. 2021 Oct;147(10):3135-3137. doi: 10.1007/s00432-021-03647-x. Epub 2021 Apr 26.

DOI:10.1007/s00432-021-03647-x

PMID:33900435

Abstract

摘要

相似文献

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?表皮生长因子受体（EGFR）抑制剂耐药中的一个问题：支原体和胞苷脱氨酶在降低肺癌患者奥希替尼活性方面是否起作用？

J Cancer Res Clin Oncol. 2021 Oct;147(10):3135-3137. doi: 10.1007/s00432-021-03647-x. Epub 2021 Apr 26.

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.未经治 NSCLC 患者中常见 EGFR 突变的一线奥希替尼治疗：UNICORN 期 2 非随机临床试验。

JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013.

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.使用奥希替尼治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的心脏事件与生存情况

JAMA Netw Open. 2024 Dec 2;7(12):e2448364. doi: 10.1001/jamanetworkopen.2024.48364.

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。

Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).一项关于奥希替尼联合或不联合雷莫西尤单抗用于酪氨酸激酶抑制剂初治的EGFR突变转移性非小细胞肺癌的多中心开放标签随机II期研究（RAMOSE试验）。

J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8.

J-REGISTER: real-world study of Japanese patients with mutation-positive NSCLC treated with first-line afatinib.J-REGISTER：对一线使用阿法替尼治疗的日本突变阳性非小细胞肺癌患者的真实世界研究。

Future Oncol. 2025 Jul;21(16):2039-2052. doi: 10.1080/14796694.2025.2514423. Epub 2025 Jun 7.

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.在真实世界中，表皮生长因子受体（EGFR）突变的非小细胞肺癌患者序贯接受酪氨酸激酶抑制剂和奥希替尼治疗后的良好生存结果。

J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18.

Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR-mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib.奥希替尼联合达拉非尼和曲美替尼对携带获得性BRAF V600E耐药突变且对奥希替尼耐药的EGFR突变型老年肺腺癌患者的疗效。

Jpn J Clin Oncol. 2025 Jul 6;55(7):832-836. doi: 10.1093/jjco/hyaf059.

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.奥希替尼在晚期 T790M 阳性非小细胞肺癌患者中德国扩大准入项目的疗效和安全性分析。

J Cancer Res Clin Oncol. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22.

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.表皮生长因子受体酪氨酸激酶抑制剂新辅助治疗表皮生长因子受体突变型非小细胞肺癌的可行性和安全性：一项荟萃分析。

Eur J Clin Pharmacol. 2024 Apr;80(4):505-517. doi: 10.1007/s00228-024-03620-w. Epub 2024 Feb 1.

引用本文的文献

Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer.设计、合成与评价双重 EGFR/AURKB 抑制剂作为治疗非小细胞肺癌的抗癌剂。

Bioorg Med Chem Lett. 2024 Mar 1;100:129612. doi: 10.1016/j.bmcl.2024.129612. Epub 2024 Jan 8.

本文引用的文献

A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX).多中心临床研究：以患者来源的肿瘤异种移植（PDTX）为指导的晚期胃肠癌个体化药物治疗。

J Cancer Res Clin Oncol. 2022 Mar;148(3):673-684. doi: 10.1007/s00432-021-03639-x. Epub 2021 Apr 17.

Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.解脲支原体感染促进肺腺癌患者对酪氨酸激酶抑制剂（TKI）的耐药性。

J Cancer Res Clin Oncol. 2021 May;147(5):1379-1388. doi: 10.1007/s00432-021-03547-0. Epub 2021 Feb 6.

The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer.微生物组在癌症及治疗疗效中的作用：聚焦肺癌

Anticancer Res. 2020 Sep;40(9):4807-4818. doi: 10.21873/anticanres.14484.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.奥希替尼治疗 EGFR 突变型非小细胞肺癌的耐药机制。

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.

Pharmacogenetics of treatments for pancreatic cancer.胰腺癌治疗的药物遗传学。

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447. doi: 10.1080/17425255.2019.1620731. Epub 2019 May 24.

RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.RX-3117（氟环戊基胞嘧啶）：一种新型的特异性抗癌代谢物，用于选择性癌症治疗。

Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. doi: 10.1080/13543784.2019.1583742. Epub 2019 Mar 16.

Targeting exon 20 insertion mutations in non-small cell lung cancer.针对非小细胞肺癌中的外显子 20 插入突变。

Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019.

The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.胰腺癌的微生物组学：从分子诊断到克服吉西他滨代谢失活引起的化疗耐药的新治疗方法。

Expert Rev Mol Diagn. 2018 Dec;18(12):1005-1009. doi: 10.1080/14737159.2018.1544495. Epub 2018 Nov 9.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.肿瘤内细菌在介导肿瘤对化疗药物吉西他滨耐药中的潜在作用。

Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.

Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.吸烟状态对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌疗效的影响：一项荟萃分析

Clin Lung Cancer. 2015 Mar;16(2):144-151.e1. doi: 10.1016/j.cllc.2014.09.008. Epub 2014 Oct 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献